A COMPREHENSIVE APPROACH TO THE STUDY OF PECULIAR PROPERTIES OF NEUROFIBROMATOSIS TYPE 1
https://doi.org/10.24060/2076-3093-2012-0-1-98-102
Abstract
Having made a literature review, the writers of the article analyze the data of native and foreign researchers on the study of neurofibromatosis type 1. They also provide the main features of pathogenesis, clinical and genetic basis of the disease, and integrate recent data on diagnosis and treatment of this disease.
About the Authors
R. N. Mustafin
Institute of Biochemistry and Genetics, Ufa Research Center
Russian Federation
Russian Federation
M. A. Bermisheva
Institute of Biochemistry and Genetics, Ufa Research Center
Russian Federation
Russian Federation
E. K. Khusnutdinova
Institute of Biochemistry and Genetics, Ufa Research Center
Russian Federation
Russian Federation
References
1. Горбунова В.Н., Имянитов Е.Н., Ледащева Т.А. Молекулярная неврология. Часть III // Опухоли головного мозга, онкогены и антионкогены. – СПб.: «Интермедика», 2004. – С. 219-232.
2. Дрозд О.В., Бабенко О.В., Семячкина А.Н. и др. Разработка подходов к ДНК-диагностике нейрофиброматоза 1-го типа в России // Медицинская генетика. – 2005. – Т. 4. – №7. – С. 322-326.
3. Макурдумян Л.А. Нейрофиброматоз I типа. Проблемы диагностики и лечения // Лечащий врач. – 2001. – №10. – С. 59-61.
4. Шнайдер Н.А. Нейрофиброматоз 1-го типа: этиопатогенез, клиника, диагностика, прогноз // Международный неврологический журнал. – 2007. – №5. – С. 24-28.
5. Banerjee S., Byrd J.N., Gianino S.M. et al. The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo // Cancer Res. – 2010. – №70(4). – Р. 1356-1366.
6. Bottillo I., Luca A., Schirinzi A. et al. Functional analysis of splicing mutations in exon 7 of NF1 gene // BMC Medical Genetics. – 2007. – №8. – P. 4-13.
7. Cunha K.G., Barboza E.P., Fonseca E.C. Identification of growth hormone receptor in localised neurofibromas of patients with neurofibromatosis type 1 // J. Clin. Pathol. – 2003. – Vol. 56. – P. 758-763.
8. Donarum E.A., Halperin R.F., Stephan D.A. Cognitive dysfunction in NF1 knock-out mice may result from altered vesicular trafficking of APP/DRD3 complex // BMC Neurosci. – 2006. – №7. – P. 22-33.
9. Ebinger M., Senf L., Wachowski O. et al. No aberrant methylation of neurofibromatosis 1 gene (NF1) promoter in pilocytic astrocytoma in childhood // Pediatric Hematology and Oncology. – 2005. – Vol. 22. - №1. – P. 83–87.
10. Feng-Chun Y., Ingram D.A., Chen S. et al. Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for NF1+/mast cells // J. Clin. Invest. – 2003. – Vol. 112. №12. – P. 1851-1861.
11. Geller M., Ribeiro M.G. Serum IgE levels in neurofibromatosis 1 // Int. J. Immunogenet. – 2006. – Vol. 33. – №2. – P. 111-115.
12. Hawes J.J., Tuskan R.G., Reilly K.M. Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies. // Neurogenetics. – 2007. – №10. – P. 1007-1019.
13. Hiatt K., Ingram D., Huddlesto H. et al. Loss of the NF1 tumor suppressor gene decreases fas antigen expression in myeloid cells // American Journal of Pathology. – 2004. – Vol. 164. – №4. – P. 1471-1479.
14. Johannessen C.M., Reczek E.E., James M.F. The NF1 tumor suppressor critically regulates TSC2 and mTOR // Proc. Natl. Acad. Sci. USA. – 2005. – Vol. 102. – №24. – P. 8573-8578.
15. Kaufmann D., Muller R., Bartelt B. et al. Spinal neurofibromatosis without cafe-au-lait macules in two families with null mutations of the NF1 gene // Am. J. Hum. Genet. – 2001. – Vol. 69. – №6. – P. 1395-1400.
16. Kilic S., Tezcan I., Sanal O., Ersoy F. Common variable immunodeficiency in a patient with neurofibromatosis. // Pediatrics International. – 2001. – Vol. 43. – P. 691-693.
17. Kluwe L., Siebert R., Gesk S. et al. Screening 500 unselected eurofibromatosis 1 patients for deletions of the NF1 gene // Human Mutation. – 2004. – Vol. 23. – №2. – P. 111-116.
18. Kluwe L., Friedrich R.E., Korf B. et al. NF1 mutations in neurofibromatosis 1 patients with plexiform neurofibromas // Human Mutation. – 2002. – Vol. 19. – №3. – P. 309-315.
19. Kweh F., Zheng M., Kurenova E. et al. Neurofibromin physically interacts with the N-terminal domain of focal adhesion kinase // Mol. Carcinog. – 2009. - Vol. 48. – №11. – P. 1005-1017.
20. Lasater E.A., Li F., Bessler W.K., Estes M.L. Genetic and cellular evidence of vascular inflammation in neurofibromin-deficient mice and humans // J. Clin. Invest. – 2010. – Vol. 120. – №3. – P. 859-870.
21. Lee P.R., Cohen J.E., Fields R.D. Immune system evasion by peripheral nerve sheath tumor // Neurosci. Lett. – 2006. – Vol. 397. – №1. – P. 126-129.
22. Luijten M., Wang Y., Smith B.T. et al. Mechanism of spreading of the highly related neurofibromatosis type 1 (NF1) pseudogenes on chromosomes 2, 14 and 22 // Eur. J. Hum. Genet. – 2000. – Vol. 8. – №3. – P. 209-214.
23. McDaniel A.S., Allen J.D., Park S.J. Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/mast cells // Blood. – 2008. – Vol. 112. – №12. – P. 4646-4654.
24. Mukhopadhyay D., Anant S., Lee R.M. et al. С > U editing of Neurofibromatosis 1 mRNA Occurs in Tumors That Express Both the Type II Transcript and apobec-1, the Catalytic Subunit of the Apolipoproten B mRNA-Editing Enzyme // Am. J. Hum. Genet. – 2002. – Vol. 70. – P. 38-50.
25. MvGillicuddy L.T., Fromm J.A., Hollstein P.E. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis // Cancer Cell. – 2009. – Vol. 16. – №1. – P. 44-54.
26. Patrakitkomjorn S., Kobayashi D., Morikawa T. Neurofibromatosis type 1 (NF1) tumor suppressor, neurofibromin, regulates the neuronal differentiation of PC12 cells via its associating protein, CRMP-2 // The Journal of Biological Chemistry. – 2008. – Vol. 283. – Р. 9399-9413.
27. Sangha N., Wu R., Kuick R. Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations // Neoplasia. – 2008. – №10. – P. 1362-1372.
28. Schepper S., Maertens O., Callens T. et al. Somatic Mutation Analysis in NF1 Cafe au lait Spots Re- veals Two NF1 Hits in the Melanocytes // Journal of Investigative Dermatology. – 2008. – Vol. 128. – P. 1050-1053.
29. Stevenson D., Zhou H., Ashrafi S. et al. Double inactivation of NF1 in tibial pseudarthrosis // The American Journal of Human Genetics. – 2006. – Vol. 79. – №1. – P. 143-148.
30. Upadhyaya M., Huson S.M., Davies M. et al. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation // The American Journal of Human Genetics. – 2007. – Vol. 80. – P. 140-151.
31. Weiqi H., Horvath E., Eklund E. A. PU.1, interferon regulatory factor (IRF)2, and the interferon consensus sequence-binding protein (ICSBP/IRF8) cooperate to activate NF1 transcription in differentiating myeloid cells // The Journal of Biological Chemistry. – 2007. – Vol. 282. – P. 6629-6643.
32. Wimmer K. Neurofibromatosis: the most frequent hereditary tumor predisposition syndrome // Wien. Med. Wochenschr. – 2005. – Vol. 155. – №11. – P. 273-280.
33. Yang G., Khalaf W., Locht L. et al. Transcriptional repression of the neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein // Molecular and cellular biology. – 2005. – Vol. 25. – №14. – P. 5869-5879.
34. Zhu C., Saberwal G., Lu Y. et al. The interferon consensus sequence-binding protein activates transcription of the gene encoding neurofibromin 1 // J. Biol. Chem. – 2004. – Vol. 279. – №49. – P. 50874-50885.
Review
For citations:
Mustafin R.N., Bermisheva M.A., Khusnutdinova E.K. A COMPREHENSIVE APPROACH TO THE STUDY OF PECULIAR PROPERTIES OF NEUROFIBROMATOSIS TYPE 1. Creative surgery and oncology. 2012;(1):98-102. (In Russ.) https://doi.org/10.24060/2076-3093-2012-0-1-98-102
Views:
577
Email this article 